Aurinia Pharmaceuticals
AUPH
#5223
Rank
HK$9.26 B
Marketcap
HK$64.68
Share price
-0.24%
Change (1 day)
9.27%
Change (1 year)

P/E ratio for Aurinia Pharmaceuticals (AUPH)

P/E ratio as of November 2024 (TTM): -15.7

According to Aurinia Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -15.7075. At the end of 2022 the company had a P/E ratio of -5.68.

P/E ratio history for Aurinia Pharmaceuticals from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-5.68-64.96%
2021-16.20.86%
2020-16.13.19%
2019-15.671.39%
2018-9.09130.85%
2017-3.9423.8%
2016-3.18-25.29%
2015-4.26-19.27%
2014-5.28

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
22.1-240.82%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.23-92.19%๐Ÿ‡บ๐Ÿ‡ธ USA
-43.8 178.57%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.